Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the long-term safety and effectiveness of Adcirca (tadalafil) in Pulmonary Arterial Hypertension (PAH) patients in the clinical practice -focused topics-

1. To evaluate the incidence of adverse events for the patients with long-term use

2. To evaluate the incidence of adverse events of decreased blood pressure, bleeding (including uterine hemorrhage), visual disturbance and sudden hearing loss.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Tadalafil

Criteria

Inclusion Criteria:

• Patients with PAH receiving Adcirca

Exclusion Criteria:Patients who meet the criteria of contraindication

• patients with hypersensitivity to tadalafil

• patients who are using any form of organic nitrate

• patients with severe renal impairment

• patients with severe hepatic impairment

• patients taking strong inhibitors of CYP3A4

• patients taking strong inducers of CYP3A4